Drug-Eluting Stent Study: How Innovation Changes Care Patterns, Costs
This article was originally published in The Pink Sheet Daily
Drug-eluting stents added $1.57 billion in annual Medicare costs in their first four years on the U.S. market, with the largest increases occurring among patients with stable coronary disease, according to observational research published April 25.
You may also be interested in...
The Senate Finance Committee signaled enhanced scrutiny into unnecessary use of stents and other implantable devices in a report released Dec. 6.
Results of the highly anticipated COURAGE trial challenge the widespread assumption that stents improve outcomes in patients with stable coronary disease, but several observers believe the findings' impact on the stent market will be modest
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.